Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017, 23(14):3756-3768. Alisertib (MLN8237) purchased from Selleck.

  • Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

    Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

  • Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm3NE42KM7:TR?= NFTGbXc4OiCq MkT3SG1UVw>? NWDsRlZyUUN3ME2wMlA1KM7:TR?= NH\USIQzPjF|Nk[4OC=>
LS174T NHjGSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3sfZJZOC53IN88US=> NF3hSIM4OiCq M1vJ[GROW09? NITlTGlKSzVyPUCuNFUh|ryP NGPVS3AzPjF|Nk[4OC=>
T84 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXiwMlUh|ryP MVi3NkBp NVW0RpE1TE2VTx?= MojWTWM2OD1yLkC5JO69VQ>? MWiyOlE{PjZ6NB?=
LS180 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqwMlUh|ryP MlvYO|IhcA>? MVHEUXNQ NFT0V4lKSzVyPUGg{txO NVe1dWF2OjZzM{[2PFQ>
SW948 NYf0SHM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTkOHM3OC53IN88US=> M1rDOVczKGh? MXnEUXNQ M1rI[2lEPTB;MTFOwG0> NHj6c2szPjF|Nk[4OC=>
HCT15 M{XxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz6NE42KM7:TR?= NFrDfZk4OiCq NWKy[mpGTE2VTx?= NIryZ41KSzVyPECuOEDPxE1? MViyOlE{PjZ6NB?=
DLD-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\3WVAvPSEQvF2= M3;mfVczKGh? MYHEUXNQ NX7jSIhCUUN3MEywMlgh|ryP NVTEfoVLOjZzM{[2PFQ>
MIP-101 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTNfm9YOC53IN88US=> MmfOO|IhcA>? NGC1ZotFVVOR MnPzTWM2OD1zIN88US=> M3\4[|I3OTN4Nki0
SNU1544 Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrEbnIxNjVizszN M4HzTFczKGh? M1LxOGROW09? MmXXTWM2OD1zIN88US=> NWjrT2huOjZzM{[2PFQ>
OCI-Ly10 MlmzR5l1d3SxeHnjJGF{e2G7 NUHjN2NmPzJiaB?= M4LMbmROW09? MUfJR|UxRTBwMEW4JO69VQ>? NF3PdowzPTh5OEOzNS=>
SU-DHL2 M{KwbGN6fG:2b4jpZ{BCe3OjeR?= NXzobplEPzJiaB?= MXTEUXNQ M{\SfmlEPTB;MD6wNUDPxE1? NXHJT|loOjV6N{izN|E>
OCI-LY7 M3L1dWN6fG:2b4jpZ{BCe3OjeR?= NXPYdFh2PzJiaB?= MUfEUXNQ MVvJR|UxRTBwMEixJO69VQ>? MUCyOVg4QDN|MR?=
SU-DHL6 MmjuR5l1d3SxeHnjJGF{e2G7 M3PyPVczKGh? Mn7vSG1UVw>? MW\JR|UxRTBwNEiyJO69VQ>? M3nwTVI2QDd6M{Ox
Jeko-1 M1;2VGN6fG:2b4jpZ{BCe3OjeR?= NFvwfmQ4OiCq Mkm0SG1UVw>? NEfmV49KSzVyPUCuNFI6KM7:TR?= MnThNlU5Pzh|M{G=
JVM-2 M1PsT2N6fG:2b4jpZ{BCe3OjeR?= NUfqfJRtPzJiaB?= NX\3cnEzTE2VTx?= MVnJR|UxRTBwMEGg{txO MmjzNlU5Pzh|M{G=
Rec-1 M33M[GN6fG:2b4jpZ{BCe3OjeR?= M4HibFczKGh? NYrxPJVjTE2VTx?= NFHyUHZKSzVyPUCuNFg4KM7:TR?= MUmyOVg4QDN|MR?=
Z-138 NHfKPZREgXSxdH;4bYMhSXO|YYm= M{\pc|czKGh? M4\uemROW09? NGK1dJZKSzVyPUCuNFE{KM7:TR?= Mnm5NlU5Pzh|M{G=
H9 MX7DfZRwfG:6aXOgRZN{[Xl? NVjGbY04PzJiaB?= NGrtfFNFVVOR NHzNNW9KSzVyPUCuOkDPxE1? NI\XSVkzPTh5OEOzNS=>
HH MXfDfZRwfG:6aXOgRZN{[Xl? MWO3NkBp MVXEUXNQ MkTLTWM2OD1yLkeg{txO NWfCRY11OjV6N{izN|E>
DND41 NFXMPFBEgXSxdH;4bYMhSXO|YYm= MmexO|IhcA>? Mm\KSG1UVw>? MYnJR|UxRTBwMTFOwG0> M17ITlI2QDd6M{Ox
CCL119 MXrDfZRwfG:6aXOgRZN{[Xl? MlfZO|IhcA>? NGPmZZpFVVOR M3mwN2lEPTB;MD6wOlIh|ryP NYjTO2N[OjV6N{izN|E>
J.Cam 1.6 MVrDfZRwfG:6aXOgRZN{[Xl? MUm3NkBp MWjEUXNQ M4PoXmlEPTB;MD6xNFUh|ryP M4HTRVI2QDd6M{Ox
Sup-T1 NIXyNo9EgXSxdH;4bYMhSXO|YYm= NFGx[Zo4OiCq NWDNZW5HTE2VTx?= NUHaUJJDUUN3ME2yMlE1OiEQvF2= MnL3NlU5Pzh|M{G=
Tib 152 NWjMdVZzS3m2b4TvfIlkKEG|c3H5 M120SVczKGh? MVzEUXNQ NVjpWFVpUUN3ME2wMlgh|ryP NHfBRYUzPTh5OEOzNS=>
MCF7 NGHyUFdHfW6ldHnvckBCe3OjeR?= NEnCWZM2KM7:TR?= NGe5d4EzPCCq NF7h[ZNFVVOR NVm5U2x4UW6mdXPld{BIOi:PIHHydoV{fA>? MXyyOVg{PDRyMR?=
MDA-MB-231 MWPGeY5kfGmxbjDBd5NigQ>? MYe1JO69VQ>? MoPWNlQhcA>? NXjLXIVETE2VTx?= NUfqN3E3UW6mdXPld{BIOy:PIHHydoV{fA>? M13lfVI2QDN2NECx
MCF7 MnW1SpVv[3Srb36gRZN{[Xl? NEGx[pk2KM7:TR?= MXWyOEBp NVXTPXB1TE2VTx?= Ml7ZSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|EwS0SFMh?= NFzLeWszPTh|NESwNS=>
MCF7 M4C0d2Z2dmO2aX;uJGF{e2G7 NHy3Nm02KM7:TR?= M1P5dFI1KGh? MY\EUXNQ MV;E[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNi=> MmTsNlU5OzR2MEG=
MCF7 NYPF[YlNTnWwY4Tpc44hSXO|YYm= NIry[IY2KM7:TR?= Mn7ZNlQhcA>? NV;ufVd[TE2VTx?= NGe1[XNF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx M2\HZlI2QDN2NECx
MCF7 NU\o[IRmTnWwY4Tpc44hSXO|YYm= MmC2OUDPxE1? NX\YV2xrOjRiaB?= NEDHXpBFVVOR MWnJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=> MkTyNlU5OzR2MEG=
MCF7 NYW1XZVuTnWwY4Tpc44hSXO|YYm= NH70W2w2KM7:TR?= Mk\YNlQhcA>? NFLOTlJFVVOR NXH6[Ih[UW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzPyCNaYCx MYKyOVg{PDRyMR?=
MDA-MB-231 M3TFWGZ2dmO2aX;uJGF{e2G7 NF20NoQ2KM7:TR?= Mlu3NlQhcA>? NULyR3BPTE2VTx?= MV7E[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ NYHxVpE6OjV6M{S0NFE>
MDA-MB-231 MlnDSpVv[3Srb36gRZN{[Xl? M{D6[FEh|ryP M3PReFI1KGh? MUTEUXNQ MWTJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNi=> MUWyOVg{PDRyMR?=
MDA-MB-231 NGrYN3ZHfW6ldHnvckBCe3OjeR?= NXfCXplQPSEQvF2= MmfTNlQhcA>? NI\5PIdFVVOR NXXDb5IxTGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJIN6[2yrbjDCNS=> M4XwT|I2QDN2NECx
MDA-MB-231 M1yzbGZ2dmO2aX;uJGF{e2G7 Mn7SOUDPxE1? M1zqVFI1KGh? MmPqSG1UVw>? NIfmbJVKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>? M4rRflI2QDN2NECx
MDA-MB-231 MmfwSpVv[3Srb36gRZN{[Xl? NWfEWIdpPSEQvF2= NHThOXozPCCq M2TZbWROW09? MnnNTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyO{BMcXBz NEDFTWwzPTh|NESwNS=>
MDA-MB-231 M4fRN2Z2dmO2aX;uJGF{e2G7 M{\XOVUh|ryP MkPsNlQhcA>? MmXRSG1UVw>? Ml;mTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIIC1Ny=> M3TIV|I2QDN2NECx
MCF7 MlT4RZBweHSxc3nzJGF{e2G7 M4nKWlUh|ryP NXzsRVRGOjRiaB?= MlzYSG1UVw>? MmDMTY5lfWOnczDhdI9xfG:2aXOg[IVifGh? M{D5R|I2QDN2NECx
MDA-MB-231 MoXuRZBweHSxc3nzJGF{e2G7 M3zNW|Uh|ryP MXKyOEBp MlLLSG1UVw>? NIizUFlKdmS3Y3XzJIFxd3C2b4TpZ{Bl\WG2aB?= MnnzNlU5OzR2MEG=
MCF7 NX;yUFZVTnWwY4Tpc44hSXO|YYm= MkLiNUDPxE1? NEi5R2w4OiCq MUPEUXNQ MUfJcoR2[2W|IHH1eI9xcGGpaXOg[IVifGh? NYSyXFh[OjV6M{S0NFE>
MDA-MB-231 NIjESoRHfW6ldHnvckBCe3OjeR?= MXGxJO69VQ>? M17PTlczKGh? MoPESG1UVw>? NIjlTJpKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= M1XofFI2QDN2NECx
U-2 OS NYTTTYNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7iblA2OCEQvF2= MlTCNlQhcA>? NV:3dnFTTE2VTx?= M4DnPWlEPTB;MU[uOkDPxE1? NXLwW|NpOjV5OUK4NVE>
MG-63 NFHMVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnWOVAh|ryP MlvJNlQhcA>? M4\HeWROW09? M2T3cWlEPTB;OT61JO69VQ>? NFzWeVAzPTd7MkixNS=>
U-2 OS MofwRZBweHSxc3nzJGF{e2G7 NX\UUmdtPSEQvF2= MWWyOEBp MoHVSG1UVw>? Mnu2TY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> NHf3[FkzPTd7MkixNS=>
MG-63 NGnmVHZCeG:ydH;zbZMhSXO|YYm= NGK4PYw2KM7:TR?= M4PsR|I1KGh? MX7EUXNQ NFP5[4dKdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp MWWyOVc6OjhzMR?=
U-2 OS M{DOWWZ2dmO2aX;uJGF{e2G7 M3PDcVUh|ryP NV\1bpJYOjRiaB?= M3\m[WROW09? NF:zOIhRem:vb4Tld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? Mne1NlU4QTJ6MUG=
MG-63 NGrke4tHfW6ldHnvckBCe3OjeR?= NV\oT5VoPSEQvF2= MV[yOEBp MYPEUXNQ NGfJfYNRem:vb4Tld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? MojjNlU4QTJ6MUG=
PANC-1 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:5OVAh|ryP NHLBeVEzPCCq MWjEUXNQ MnfNTWM2OD15LkGg{txO NYrMZ4xWOjV4M{KyNlU>
BxPC-3 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUe1NEDPxE1? NFnMfIgzPCCq M1W5SGROW09? NXjlWYhTUUN3ME22Mlgh|ryP MlnGNlU3OzJ{MkW=
PANC-1 MljWSpVv[3Srb36gRZN{[Xl? NVfuOINkPSEQvF2= M4T6PFI1KGh? M3SxcmROW09? NFnQeJlKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V? Mn3QNlU3OzJ{MkW=
BxPC-3 NYDwOpFuTnWwY4Tpc44hSXO|YYm= MUK1JO69VQ>? MUKyOEBp M1\jOGROW09? MV3JcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U> MoraNlU3OzJ{MkW=
PANC-1 MYLGeY5kfGmxbjDBd5NigQ>? M3f0bVUh|ryP MkK3NlQhcA>? MnSxSG1UVw>? NUWwOGs5UW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? MoP5NlU3OzJ{MkW=
BxPC-3 M17kTGZ2dmO2aX;uJGF{e2G7 NFzRPZY2KM7:TR?= MViyOEBp M325NGROW09? NYDU[|J3UW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? Mn\SNlU3OzJ{MkW=
SKOV3 NFXXeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxNFAh|ryP NWrCZmJbOjRiaB?= MmnISG1UVw>? NFz2[YRKSzVyPUKwMlQ5KM7:TR?= MmH1NlU3OjR5NUC=
OVCAR4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrYXIIyODBizszN NHrwUmMzPCCq MYHEUXNQ MoTrTWM2OD1{Mj6xN{DPxE1? NIrYVYUzPTZ{NEe1NC=>
SKOV3 NIfWUYhHfW6ldHnvckBCe3OjeR?= M{\FVlUh|ryP NVO1NHhFPzJiaB?= NI\hcmhFVVOR MlyyTY5lfWOnczDHNk9OKGG{cnXzeC=> NYqzRphPOjV4MkS3OVA>
OVCAR4 MkHOSpVv[3Srb36gRZN{[Xl? MlG5OUDPxE1? M1zOZVczKGh? M3y5bmROW09? M{f1UGlv\HWlZYOgS|IwVSCjcoLld5Q> Mn\hNlU3OjR5NUC=
SKOV3 M3vsTmFxd3C2b4Ppd{BCe3OjeR?= NHe2SVA2KM7:TR?= NE\tPIUzPCCq Mnr5SG1UVw>? NH2zOFRKdmS3Y3XzJIFxd3C2b4Ppdy=> NXrNNnBHOjV4MkS3OVA>
OVCAR4 NHHxVJFCeG:ydH;zbZMhSXO|YYm= Mmj1OUDPxE1? MlXONlQhcA>? MX;EUXNQ M{DHO2lv\HWlZYOgZZBweHSxc3nz MV[yOVYzPDd3MB?=
AGS MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XNRVI2KM7:TR?= M2XsR|I1KGh? M1z5TmROW09? NWWwOINtUUN3ME2xPU4xQSEQvF2= Ml;ENlU3ODl7MkO=
NCI-N78 NI\uS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLNNlUh|ryP M3jycVI1KGh? NYXaOYVXTE2VTx?= M3:zRmlEPTB;Mk[uN|Mh|ryP MXKyOVYxQTl{Mx?=
AGS MX\BdI9xfG:|aYOgRZN{[Xl? NEHrdmg2KM7:TR?= NWDk[4lMOjRiaB?= MlHMSG1UVw>? MYrJcoR2[2W|IHHwc5B1d3Orcx?= NIeyfJgzPTZyOUmyNy=>
NCI-N78 NFTubGJCeG:ydH;zbZMhSXO|YYm= NX;LN4NjPSEQvF2= MmLBNlQhcA>? MULEUXNQ M3Tr[2lv\HWlZYOgZZBweHSxc3nz Mn\RNlU3ODl7MkO=
AGS NInPbVRHfW6ldHnvckBCe3OjeR?= MkHOOUDPxE1? M4DJZ|I1KGh? Mke4SG1UVw>? NHX0dYZKdmS3Y3XzJJRp\SCjdYTvdIhi\3l? M4fTb|I2PjB7OUKz
NCI-N78 NHX4RndHfW6ldHnvckBCe3OjeR?= NYTkTpBpPSEQvF2= NVvWXoxuOjRiaB?= NYPZVYlDTE2VTx?= NH\CWZhKdmS3Y3XzJJRp\SCjdYTvdIhi\3l? MkDqNlU3ODl7MkO=
HSC-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LqS|Eh|ryP NIH4fmI1QCCq Mk[xTWM2OD1yLkW0JO69VQ>? NYXuTZo5OjV|Nk[xOFM>
GB30 NGXCZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrv[W4yKM7:TR?= MmjsO{Bl MofJSG1UVw>? NGe3XXRKSzVyPUCuNFEyKM7:TR?= NE\OXlkzPTFyNkSyPC=>
GB9 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jpZlEh|ryP NVPJV3Z4PyCm MlPHSG1UVw>? NHX0TGJKSzVyPUCuNFI1KM7:TR?= M3W4NVI2OTB4NEK4
GB169 NV:yPHNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnjNUDPxE1? NEDhSnU4KGR? NFexT4ZFVVOR NH3uNIdKSzVyPUCuNFMzKM7:TR?= MnTSNlUyODZ2Mki=
T24 MYfGeY5kfGmxbjDBd5NigQ>? MkLMNUDPxE1? MWK0PEBp NVvVd2pJTE2VTx?= M1uwNGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= Mny5NlM1ODN4M{O=
RT4 NXrufGFoTnWwY4Tpc44hSXO|YYm= MoTlNUDPxE1? NHnneWU1QCCq NHL1NFdFVVOR MY\JcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MVuyN|QxOzZ|Mx?=
UM-UC-3 NHXIeZVHfW6ldHnvckBCe3OjeR?= MVixJO69VQ>? MojhOFghcA>? MorYSG1UVw>? MXXJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 M1XSZlI{PDB|NkOz
T24 MmC3RZBweHSxc3nzJGF{e2G7 MoPnN{4yPiEQvF2= NW\weXJuQTZiaB?= NF\QVHpFVVOR MV3JR|UxRTBwMEOwOkDPxE1? Mn;LNlM1ODN4M{O=
RT4 M{TNNWFxd3C2b4Ppd{BCe3OjeR?= M4LOeVMvOTZizszN NGD5fmU6PiCq MWTEUXNQ NFHqVGNKSzVyPUCuNVE6QCEQvF2= NULSSox5OjN2MEO2N|M>
UM-UC-3 NWrB[md7SXCxcITvd4l{KEG|c3H5 NYjjfGZuOy5zNjFOwG0> NWnB[G9lQTZiaB?= MYHEUXNQ M4DwV2lEPTB;MD6wOFQ6KM7:TR?= NYL4SG1tOjN2MEO2N|M>
OVCAR-5 NIrXcGtHfW6ldHnvckBCe3OjeR?= Mmm4OVAhdk1? NIjVb5dKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?= Mm\tNlM{OzR|Mke=
SKOV3ip2 M2TKT2Z2dmO2aX;uJGF{e2G7 NHjlfoQ2OCCwTR?= NWn6bpdUUW6qaXLpeJMh[2WubDDtbYdz[XSrb36= NWTDW2M6OjN|M{SzNlc>
S462 NEC5SndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mke2NVAxKM7:TR?= MYe3NkBp NGPB[45FVVOR NIfiTVNCfHSnboXheIV{KGOnbHyg[5Jwf3Sq NFHJZpgzOzN{OEGxOC=>
2884 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH5Z5QyOTByIN88US=> MXm3NkBp NFvz[JhFVVOR MU\BeJRmdnWjdHXzJINmdGxiZ4Lve5Rp MVuyN|MzQDFzNB?=
2885 NF;w[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\UXYEyODBizszN MYm3NkBp MmXvSG1UVw>? NXrpbFlCSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= NYDxN3JFOjN|MkixNVQ>
CRL-2396 MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoGwNVAxKM7:TR?= NWjVbZJ2f2G2ZYK= M2POe2lEPTB;MD6wPVIh|ryP NWnWWGNlOjNzNUO1NlQ>
TIB-48 M2X5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXGbHcyODBizszN NFnqemR4[XSnch?= NYrmXmR7UUN3ME2wMlA5QCEQvF2= MnfCNlMyPTN3MkS=
CRL-2396 M{HvXWN6fG:2b4jpZ{BCe3OjeR?= NVL4bZN4OSEQvF2= MmDrOFghcA>? M3PrT5difGW{ MWXJcoR2[2W|IHHwc5B1d3Orcx?= NI\mdmozOzF3M{WyOC=>
TIB-48 NUe4RWJQS3m2b4TvfIlkKEG|c3H5 NVPnNWtDOSEQvF2= MonsOFghcA>? M3LhRZdifGW{ NXX6N5FDUW6mdXPld{BieG:ydH;zbZM> NH\DNHQzOzF3M{WyOC=>
AGS NUL0O3NGS3m2b4TvfIlkKEG|c3H5 M1TFOVAvPSEQvF2= NIfTSWwzPCCq NHzrSYRFVVOR NWnkO2RvTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy= MVuyNlk4OjZzMR?=
FLO-1 NX6zNXRtS3m2b4TvfIlkKEG|c3H5 M4PUb|AvPSEQvF2= NWGwTGJEOjRiaB?= MXjEUXNQ MVrE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? MVuyNlk4OjZzMR?=
OE33 M1rzdGN6fG:2b4jpZ{BCe3OjeR?= M2LVNlAvPSEQvF2= NWO5SZB5OjRiaB?= M4LXcWROW09? MXjE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? MkfrNlI6PzJ4MUG=
SKLMS MVHDfZRwfG:6aXOgRZN{[Xl? MV[3OUBvVQ>? NInQVVM6PiCq MmCwTY5lfWOnczDhdI9xfG:|aYO= MlPrNlI5OjF7OUe=
Leio285 NGrWflFEgXSxdH;4bYMhSXO|YYm= NXrlNpNzPzVibl2= MmrOPVYhcA>? NIGyPXdKdmS3Y3XzJIFxd3C2b4Ppdy=> MmPpNlI5OjF7OUe=
Mes-Sa NHLTRWJEgXSxdH;4bYMhSXO|YYm= M3HEXVc2KG6P NIm4PY46PiCq MnHvTY5lfWOnczDhdI9xfG:|aYO= NUKweGhqOjJ6MkG5PVc>
DAOY Mmi5R5l1d3SxeHnjJGF{e2G7 MWSxNEDPxE1? MYO3NkBp MVnEUXNQ M1XDTWlEPTB;MD6wOEDPxE1? NWLCfXQ2OjJ4NkmzN|U>
IMR32 NGfPXmJEgXSxdH;4bYMhSXO|YYm= NYjzT2FFOTBizszN NUDMb48yPzJiaB?= NXnB[3I{TE2VTx?= M4jPTGlEPTB;MD6wN{DPxE1? M{DhOFIzPjZ7M{O1
Molt-4 NYHjSnI3S3m2b4TvfIlkKEG|c3H5 NHTSXJUyOCEQvF2= MYS3NkBp NH;IcWJFVVOR MkPYTWM2OD1yLkCyJO69VQ>? NF64NFEzOjZ4OUOzOS=>
MOLM-13 NFTVO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljQN{DPxE1? MV63NkBp M3ribGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MXuyNlQ5QDJ2OR?=
HL-60 NXrofY9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfaeGY{KM7:TR?= M3npUVczKGh? M3jmRmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= M2fYeVIzPDh6MkS5
MV4-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPue3dmOyEQvF2= NFjkTVA4OiCq NITKWnRFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NHTRbXozOjR6OEK0PS=>
SKM-1 NHzPVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHi[o4yOyEQvF2= M33I[VczKGh? MV;EbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MW[yNlQ5QDJ2OR?=
SH2 NX3iPJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYizJO69VQ>? M1;oWlczKGh? MnLqSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NETEfpgzOjR6OEK0PS=>
NOMO-1 M4\IeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnrW5U{KM7:TR?= NWH0NIFoPzJiaB?= MWTEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NF3OTIszOjR6OEK0PS=>
OCL-AML2 M2XUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPoVHB5OyEQvF2= MmDEO|IhcA>? M3HRUGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MVuyNlQ5QDJ2OR?=
PL-21 NV\ZPW9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr6eZM{KM7:TR?= NFXhWpY4OiCq NH65WYhFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NY\KNG0zOjJ2OEiyOFk>
KG-1 NEP4bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy2R456OyEQvF2= M2jDNFczKGh? MkD5SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NYXqfpJQOjJ2OEiyOFk>
A172 M{nOUGN6fG:2b4jpZ{BCe3OjeR?= NGTkeWMyODBizszN MV[yOEBp NF;2S2hFVVOR MXnJR|UxRTBwMUKwJO69VQ>? NEi2dHQzOjJ5NEO5PS=>
U87 NVv1VJV4S3m2b4TvfIlkKEG|c3H5 M3\pZVExOCEQvF2= M1HiSFI1KGh? MV7EUXNQ M1ryUmlEPTB;MD6xNFUh|ryP MVeyNlI4PDN7OR?=
U251 MV;DfZRwfG:6aXOgRZN{[Xl? NWXnVFZLOTByIN88US=> Mn;PNlQhcA>? MnjiSG1UVw>? NGrLUZhKSzVyPUCuNVAxKM7:TR?= M33lT|IzOjd2M{m5
T98 M{XxeGN6fG:2b4jpZ{BCe3OjeR?= M4f1eVExOCEQvF2= NHfmb2kzPCCq NUTTOmlzTE2VTx?= MXTJR|UxRTBwMUK1JO69VQ>? M1LCelIzOjd2M{m5
LN18 MkDQR5l1d3SxeHnjJGF{e2G7 MYqxNFAh|ryP MnHkNlQhcA>? MULEUXNQ MnTOTWM2OD1yLkKxNEDPxE1? NFzTfoYzOjJ5NEO5PS=>
LN443 MY\DfZRwfG:6aXOgRZN{[Xl? M3Th[|ExOCEQvF2= NFfyclYzPCCq MV;EUXNQ NEez[I1KSzVyPUCuNlIxKM7:TR?= NXLrb4xKOjJ{N{SzPVk>
HF66 NFPoeHlEgXSxdH;4bYMhSXO|YYm= M4LOblExOCEQvF2= M3nVe|I1KGh? Ml63SG1UVw>? M3;BRWlEPTB;MD6yNlUh|ryP NWrQfVR6OjJ{N{SzPVk>
HF2303 M4XUfmN6fG:2b4jpZ{BCe3OjeR?= NVq0fmVJOTByIN88US=> NWLrTFMzOjRiaB?= NV3TXHBLTE2VTx?= NYP5bpFvUUN3ME2wMlA3OCEQvF2= NYLZSpNVOjJ{N{SzPVk>
HF2359 M2jVNWN6fG:2b4jpZ{BCe3OjeR?= NGraSZMyODBizszN MmP0NlQhcA>? NULDfGFtTE2VTx?= MV7JR|UxRTBwME[wJO69VQ>? MVqyNlI4PDN7OR?=
HF2414 MlLQR5l1d3SxeHnjJGF{e2G7 M1nzNVExOCEQvF2= M4jBSFI1KGh? Mk\3SG1UVw>? MWPJR|UxRTBwMEiwJO69VQ>? NFH1W2EzOjJ5NEO5PS=>
A-673 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTnU2hOOTBizszN NV7K[49TQTZiaB?= M3HEO2ROW09? NIHSRpdKSzVyPUCuNFMzKM7:TR?= NXThOYZPOjF2NEi1PVE>
TC-32 NXvZdYR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInMfpQyOCEQvF2= M3X6dFk3KGh? MXLEUXNQ MYHJR|UxRTBwMEO5JO69VQ>? NXPzN41DOjF2NEi1PVE>
TC-71 NUXGcXdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLZWlgyOCEQvF2= Mn\3PVYhcA>? M1vzUmROW09? MVnJR|UxRTBwMUCyJO69VQ>? NITGeWozOTR2OEW5NS=>
SK-N-MC NHzXWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXyxNEDPxE1? MYS5OkBp M3y0SWROW09? MmLnTWM2OD1yLkC3NkDPxE1? NGO2NoMzOTR2OEW5NS=>
CHLA-9 NV\aOmtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\3NVAh|ryP M4XXclk3KGh? M4fCb2ROW09? Mmj5TWM2OD1yLkCxPEDPxE1? MWiyNVQ1QDV7MR?=
CHLA-10 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HCWVExKM7:TR?= NFLqTYM6PiCq MnPDSG1UVw>? MVHJR|UxRTBwME[wJO69VQ>? NUi3PHZEOjF2NEi1PVE>
CHLA-25 MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zaSlExKM7:TR?= M3fHfVk3KGh? M4XVVGROW09? M2HhOGlEPTB;MD6xOlgh|ryP NXXybVN{OjF2NEi1PVE>
CHLA-32 NH3xSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33WXVExKM7:TR?= NVTl[20xQTZiaB?= MUnEUXNQ M{XPOmlEPTB;MD6xN|Yh|ryP MUCyNVQ1QDV7MR?=
CHLA-56 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Lr[FExKM7:TR?= M2DDclk3KGh? MofmSG1UVw>? MoPaTWM2OD1zMDFOwG0> NXPmW|lXOjF2NEi1PVE>
CHLA-258 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTpNVAh|ryP M4\6O|k3KGh? Ml;RSG1UVw>? Ml7sTWM2OD1yLkGzNkDPxE1? MYSyNVQ1QDV7MR?=
COG-E-352 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mxT|ExKM7:TR?= M3XySVk3KGh? MX\EUXNQ M2\WR2lEPTB;MD6wOFMh|ryP NYTJeWVCOjF2NEi1PVE>
CHLA-90 M1:5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVOzO5BvOTBizszN M{KzXVk3KGh? NX\vSGlOTE2VTx?= MUTJR|UxRTBwME[xJO69VQ>? MXSyNVQ1QDV7MR?=
CHLA-119 M{DnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmxNEDPxE1? NVS0bIx5QTZiaB?= MYHEUXNQ NYnjTo1iUUN3ME2wMlAzOiEQvF2= NHv5c2ozOTR2OEW5NS=>
CHLA-122 NHPJVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUD0Z3pvOTBizszN NG\oO2M6PiCq MX\EUXNQ M3PjemlEPTB;MD6wNVkh|ryP MUCyNVQ1QDV7MR?=
CHLA-136 NInVU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH5UHEyOCEQvF2= MX[5OkBp NX;wNoZPTE2VTx?= NFziXW1KSzVyPUCuNFM6KM7:TR?= NF7ZWGYzOTR2OEW5NS=>
CHLA-140 M3fSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\BNVAh|ryP MmCzPVYhcA>? NXjibFVFTE2VTx?= M3[2XmlEPTB;MD6wNlYh|ryP M4\yZVIyPDR6NUmx
LA-N-6 NF3lSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXftfGlEOTBizszN NXezRmtrQTZiaB?= MV\EUXNQ MX\JR|UxRTBwMEW0JO69VQ>? MViyNVQ1QDV7MR?=
NB-1643 M362Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4foUVExKM7:TR?= MYS5OkBp NUnnU3h3TE2VTx?= NFrsS2RKSzVyPUCuNFM4KM7:TR?= MVOyNVQ1QDV7MR?=
NB-EBc1 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfVclYyOCEQvF2= NHv6elI6PiCq NG\4NIhFVVOR MXTJR|UxRTBwMEWwJO69VQ>? NW\SdWRzOjF2NEi1PVE>
SK-N-BE-1 NY\ycY8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexNEDPxE1? NV\acGdnQTZiaB?= NUTj[IU3TE2VTx?= Mnq5TWM2OD1yLkCyPEDPxE1? MYmyNVQ1QDV7MR?=
SK-N-BE-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO5cVIyOCEQvF2= M4XhVlk3KGh? NITQRopFVVOR NV\3eWREUUN3ME2wMlA{PiEQvF2= NIK5[24zOTR2OEW5NS=>
SMS-KAN NUnxfWkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\sOVVyOTBizszN MmK5PVYhcA>? NITHN4hFVVOR M3PIV2lEPTB;MD6wN|Qh|ryP MkHLNlE1PDh3OUG=
SMS-KANR MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjrVGdSOTBizszN NHv4[Y06PiCq NH23SHpFVVOR NF;FOVlKSzVyPUCuNFI3KM7:TR?= NIfSbWgzOTR2OEW5NS=>
SMS-KCN MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXCNVAh|ryP MVe5OkBp NXHoSYMzTE2VTx?= NYPwVYhvUUN3ME2wMlAyQSEQvF2= MnzGNlE1PDh3OUG=
SMS-KCNR MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3IXHYyOCEQvF2= MUG5OkBp MVfEUXNQ M2DRN2lEPTB;MD6wNVAh|ryP NEDtUZgzOTR2OEW5NS=>
SMS-LHN NWTwbFhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO5RZYyOCEQvF2= NGrsZ5M6PiCq MoDzSG1UVw>? MmPhTWM2OD1yLkCzNkDPxE1? M3TBelIyPDR6NUmx
SMS-MSN MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\pWFgyOCEQvF2= Mlr1PVYhcA>? MWnEUXNQ MmH2TWM2OD1yLkCyNkDPxE1? MUSyNVQ1QDV7MR?=
SMS-SAN MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXMb|QyOCEQvF2= NGDLeYo6PiCq M4jnVWROW09? M3f5dGlEPTB;MD6wNlAh|ryP NFXmdm8zOTR2OEW5NS=>
Granta-4 MnnpR5l1d3SxeHnjJGF{e2G7 MUixNEDPxE1? M4LyTVch\A>? NEPsTXNKSzVyPUCuNFQxKM7:TR?= MWKyNVI6OTh4Nx?=
DB MXrDfZRwfG:6aXOgRZN{[Xl? NITIcIEyOCEQvF2= M2exUFch\A>? NXnvV|lLUUN3ME2wMlA1OiEQvF2= MYSyNVI6OTh4Nx?=
RL NHPPdlVEgXSxdH;4bYMhSXO|YYm= MYmxNEDPxE1? M33TS|ch\A>? M1\VdWlEPTB;MD6wNVUh|ryP MnT1NlEzQTF6Nke=
K562 M3f1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG0NXZ5OTBizszN NGP0Z2Q6PiCq NGjleFdKSzVyPUCuNFg4KM7:TR?= M2njNlIyODlzNkOz
LAMA-84 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqxNEDPxE1? NEW3cHY6PiCq NUnvWVIxUUN3ME2wMlA2PyEQvF2= MorONlExQTF4M{O=
MM15 NXPmZ|JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrnb2E1KM7:TR?= NHTBUG04OiCq MWnEUXNQ MnuyTWM2OD1yLkGzJO69VQ>? MmjjNlA{QDJ6NES=
OPM1 NIHj[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:0JO69VQ>? MX:3NkBp M33mNmROW09? NIjkUWJKSzVyPUCuNFMh|ryP NUni[mJiOjB|OEK4OFQ>
RPM1 NUXXcFZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjZbVQ6PCEQvF2= NVH6V3lmPzJiaB?= MlfkSG1UVw>? MoK5TWM2OD1zMD6zNkDPxE1? M{nvUlIxOzh{OES0
INA6 NV3xXHJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv1eGREPCEQvF2= M3vnZlczKGh? NHjUdlBFVVOR MnP3TWM2OD1yLkCwNkDPxE1? MV6yNFM5Ojh2NB?=
OPM2 NHnJTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXDeo81KM7:TR?= MVG3NkBp MlXkSG1UVw>? MY\JR|UxRTRwM{eg{txO M1jGfFIxOzh{OES0
MM1R NXGwS|cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTRNFN6PCEQvF2= NVzVUY5HPzJiaB?= NYjOfVQ1TE2VTx?= NYOwcG1mUUN3ME2xMlY5KM7:TR?= MXeyNFM5Ojh2NB?=
DOX40 M2X1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LMcVQh|ryP NIXPdHY4OiCq NYX2NnF6TE2VTx?= NWDnempvUUN3ME21MlQ5KM7:TR?= M17udFIxOzh{OES0
LR5 NXTHcFJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVe0JO69VQ>? NVvnRXo2PzJiaB?= MlzBSG1UVw>? M2fw[WlEPTB;Mj61N{DPxE1? NEX3VWEzODN6Mki0OC=>
U266 Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ntSVQh|ryP Mn7IO|IhcA>? MUDEUXNQ MlHTTWM2OD1zLkSzJO69VQ>? MVeyNFM5Ojh2NB?=
RD NYG1elhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[xNEDPxE1? NFH1OJA6PiCq NV7tUWZIUUN3ME2wMlIzQCEQvF2= M1;4NVIxOTB6M{O4
Rh41 M3m5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\sRoJnOTBizszN MU[5OkBp MlX2TWM2OD1yLkC5NEDPxE1? MX[yNFExQDN|OB?=
Rh30 NXXVbHhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGxVnIyOCEQvF2= NX\uSmZlQTZiaB?= M2HtZmlEPTB;MD6yN|Ah|ryP NV3XXmxQOjBzMEizN|g>
BT-12 NGP5Z2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknLNVAh|ryP NV7BNGFGQTZiaB?= M2exfmlEPTB;MD6wOlAh|ryP MmjwNlAyODh|M{i=
CHLA-266 NUPneJJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqxNEDPxE1? MonmPVYhcA>? MorGTWM2OD1yLkC3NkDPxE1? M{XOWFIxOTB6M{O4
TC-71 M1LGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e1OFExKM7:TR?= M3PpN|k3KGh? M4TKSGlEPTB;MD6xNFIh|ryP NXfGe281OjBzMEizN|g>
SJ-GBM2 M1zpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjQc3B1OTBizszN MljiPVYhcA>? M1W3XmlEPTB;MD6wOVAh|ryP NUHGUGtnOjBzMEizN|g>
NALM-6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzQWFAyOCEQvF2= M{HkTVk3KGh? NFvhR5hKSzVyPUCuNFYzKM7:TR?= NYiwTJFLOjBzMEizN|g>
COG-LL-317 M{HSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m0d|ExKM7:TR?= MXS5OkBp MoG0TWM2OD1yLkC0O{DPxE1? NFnZPYYzODFyOEOzPC=>
RS4-11 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH0c|ZXOTBizszN NYjJdpd5QTZiaB?= NYLMOndwUUN3ME2wMlAyQCEQvF2= M4fLbVIxOTB6M{O4
MOLT-4 M3HH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPySVRmOTBizszN NXLzNnVIQTZiaB?= MonQTWM2OD1yLkCyOkDPxE1? Ml\aNlAyODh|M{i=
CCRF-CEM MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofKNVAh|ryP MmH2PVYhcA>? NUO1NIJQUUN3ME2wMlA6PCEQvF2= NYOwTFlwOjBzMEizN|g>
Kasumi-1 Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DBTFExKM7:TR?= MVq5OkBp NYPOZoN{UUN3ME2wMlExOyEQvF2= MUSyNFExQDN|OB?=
Karpas-299 M1PsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvaNVAh|ryP NIPZbIU6PiCq M2C5WGlEPTB;MD6wN|gh|ryP MV:yNFExQDN|OB?=
Ramos-RA1 NVXEfoxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWexNEDPxE1? MmfTPVYhcA>? NFfIVnZKSzVyPUCuNVI4KM7:TR?= MXKyNFExQDN|OB?=

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+30% PEG300+5%Tween-80+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Recruiting Estrogen Receptor Status|HER2/Neu Negative|Invasive Breast Carcinoma|Postmenopausal|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) July 6 2017 Phase 2
NCT02700022 Terminated Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals Inc. October 2016 Phase 1
NCT02812056 Withdrawn Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals Inc. September 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado Denver May 13 2016 Phase 1
NCT02560025 Active not recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02530619 Active not recruiting Acute Megakaryoblastic Leukemia|Myelofibrosis|Primary Myelofibrosis Northwestern University|The Leukemia and Lymphoma Society|Millennium Pharmaceuticals Inc.|National Cancer Institute (NCI) October 2015 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products5

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID